Special Issue "Anticancer Drugs Activity and Underlying Mechanisms"
Deadline for manuscript submissions: closed (30 April 2021) | Viewed by 10284
A printed edition of this Special Issue is available here.
Interests: food; medicinal chemistry; bioactive products; nutraceuticals; phytochemicals; natural products extraction and isolation; antioxidants; anti-inflammatory; antimicrobials enzyme inhibition; cancer; cell biology
Special Issues, Collections and Topics in MDPI journals
You are cordially invited to contribute to this Special Issue entitled “Anticancer Drugs Activity and Underlying Mechanisms”. As you know, cancer is a multifactorial disease and its onset and progression are very complex. Even though prevention, early diagnoses, and new therapies have been implemented, cancer is still the second leading cause of death worldwide. The continuous fight against cancer has led several researchers to develop new, more powerful, and safer molecules or repurpose old ones with unknown antitumor activities. A trend to customize the therapy has been recorded, together with the need to design and study drugs selectively targeting a cell component, with few toxic effects. However, clinical experiences have reinforced the idea that targeting a single cell component may not be the real mechanism by which drugs produce the desired effect; indeed, cells could become resistant to the treatment, for instance, activating compensatory pathways. Thus, the multi-target drugs concept and the individuation of the underlying mechanisms represent rich and fertile fields for drug research and development. The major issue of the emergence of multidrug resistance and relapse has been faced using, for instance, genomic/proteomic profiling technologies and selective molecular targeted therapies. This Special Issue addresses several old chemotherapeutic drugs or newer ones, whose cellular mechanisms are not well explicated and detailed. Original research papers or review articles on the design, synthesis, and evaluation of drugs or metal complexes targeting biomolecules such as tubulin and topoisomerase are very welcome.
Dr. Domenico Iacopetta
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2300 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Design and synthesis of new antitumor drugs
- Natural or chemically modified drugs
- Carbazoles derivatives
- Metal complexes
- Human topoisomerases inhibitors
- Drugs interfering with cytoskeleton dynamics
- Drug repurposing
- Kinases inhibitors
- Intercalating agents
- Mitochondria-targeting drugs
- Steroid-hormones-targeting drugs